QUOTE AND NEWS
Motley Fool  Feb 6  Comment 
The drugmaker's stock soared last month on a rich buyout offer from Japan's Takeda Pharmaceutical.
newratings.com  Feb 6  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase or ALK inhibitor, brigatinib, to the European Medicines Agency...
Motley Fool  Jan 17  Comment 
Find out why these stocks have soared during the post-election rally.
FiercePharma  Jan 13  Comment 
FiercePharmaAsia: Takeda’s $5.2B deal for Ariad and $125M with Maverick, Valeant’s $820M Dendreon sell to Chinese company, and more aliu Fri, 01/13/2017 - 08:26
Motley Fool  Jan 13  Comment 
Find out what has sent these winners higher and whether they have more room to run.
Reuters  Jan 10  Comment 
* If deal is terminated by co, to enter definitive agreement with respect to superior proposal, co to pay termination fee of $169 million Source text - http://bit.ly/2ido9QF Further company...
Benzinga  Jan 10  Comment 
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday January 9, 2017. Takeda to Acquire ARIAD Pharmaceuticals, Inc. for $24/Share Cash The Deal: Takeda Pharmaceutical and ARIAD Pharmaceuticals, Inc....




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki